Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Blocking Galactin-3 Binding Prevents Metastasis in Various Cancers

By BiotechDaily International staff writers
Posted on 03 Apr 2013
A small molecule derived from a glycoprotein that protects cod from freezing binds and inhibits galectin-3 and prevents metastasis in various cancers, including prostate adenocarcinoma.

Galectin-3 (gal3) is one of the 14 recognized mammalian lectins. This protein weighs approximately 30 kDa and, like all galectins, contains a carbohydrate-recognition-binding domain of about 130 amino acids that enables the specific binding of beta-galactosides. Gal3 is expressed in cells in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. This protein has been shown to be involved in cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. Gal3 recognizes the Thomsen-Friedenreich disaccharide (TFD, galactose-N-acetylgalactosamine) that is present on the surface of most cancer cells and is involved in promoting angiogenesis, tumor-endothelial cell adhesion, and metastasis of prostate cancer cells, as well as evading immune surveillance through killing of activated T-cells.

Investigators at the University of Maryland School of Medicine (Baltimore, USA) isolated a glycopeptide (TDF100) from cod that presents the disaccharide (galactose-N-acetylgalactosamine) recognized by gal3.

They reported in the March 11, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that TFD100 blocked gal3-mediated angiogenesis, tumor-endothelial cell interactions, and metastasis of prostate cancer cells in mice at nanomolar levels. Apoptosis of activated T-cells—induced by either recombinant gal3 or prostate cancer patient serum-associated gal3—was inhibited by nanomolar concentrations of TFD100.

“This study is among the first to explore the therapeutic utility of a bioactive cod TFD-containing glycopeptide to inhibit prostate cancer from progressing,” said senior author Dr. Hafiz Ahmed, assistant professor of biochemistry and molecular biology at the University of Maryland School of Medicine. “The TFD (Thomsen-Friedenreich disaccharide) antigen in the fish protein is hidden in normal human cells but is exposed on the surface of cancer cells and is believed to play a key role in how cancer spreads.”

“The use of natural dietary products with antitumor activity is an important and emerging field of research,” said Dr. Ahmed. “Understanding how these products work could allow us to develop foods that also act as cancer therapeutics and agents for immunotherapy.”

Related Links:
University of Maryland School of Medicine




Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.